This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bardet - Biedl syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • characterised by retinal dystrophy, hypogonadism, reduced IQ, obesity (+/- polydactyly) plus renal abnormalities (calcyceal cysts or diverticula, calyceal blunting or clubbing, fetal lobulation)
  • this syndrome does not have neurological symptoms (spastic paraplegia) - this differentiates it from Laurence-Moon-Biedl syndrome
  • recessive inheritance
    • genetic locus:
      • BBS1 has no linkage to chromosome 16
      • BBS2 is mapped to markers on chromosome 16.
  • epidemiology
    • incidence 1: 160,000; in Newfoundland the incidence is much higher at 1: 16,000

NICE guidance setmelanotide in Bardet-Biedel syndrome

  • recommends setmelanotide as an option for treating obesity and hyperphagia in genetically confirmed BBS in people aged ≥ 6 years, only if they are aged between 6 and 17 years when treatment starts
  • can carry on having setmelanotide as adults until they need to stop

Main contributor for Bardet - Biedl syndrome section: Thomas Waterfield (October 2007).

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page